Small Molecules
19 September 2024
Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza Viruses18 September 2024
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-324718 September 2024
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer18 September 2024
Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial16 September 2024
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study16 September 2024
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 202416 September 2024
Linnaeus Therapeutics Announces Presentation of Positive Clinical Data of LNS8801 in Metastatic Melanoma at 2024 ESMO Annual Meeting16 September 2024
Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder15 September 2024
Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial15 September 2024
New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer15 September 2024
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer13 September 2024
Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)13 September 2024
HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 202410 September 2024
Cytokinetics Announces Data From Phase 1 Study of CK-402158610 September 2024
Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of GlioblastomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports